Policy | February 01, 2026
A nationwide network of over 1,000 accredited clinical trial sites will be created to accelerate drug development timelines and enhance research credibility
The Union Budget makes a clear and timely choice by placing biopharma at the centre of India’s next manufacturing wave
India in the Changing Landscape of Life-Sciences Research & Development
The initiative is being led through the Bank’s CSR programme, Parivartan, in partnership with the Indian Cancer Society
BioNTech is positioning 2026 as a defining year in its transition toward a multi-product oncology company
Sabitha highlighted the growing relevance of minimally invasive therapies in modern medicine
Coverage has been significantly strengthened across key therapeutic categories, including anti-tubercular, anti-diabetic and anti-cancer medicines, as well as iron supplements, thereby ensuring more comprehensive standardisation of medicines used under various National Health Programmes
Indian Pharmacopoeia is now recognised in 19 countries, reflecting growing international confidence in India’s regulatory and scientific capabilities
The pharmaceutical giant now expects 2026 revenues to land between $59.5 billion and $62.5 billion
Subscribe To Our Newsletter & Stay Updated
